Kevin Quon
Insider ownership, small-cap, long-term horizon, dividend investing

Is It Too Early To Invest In Versartis?

The Hot IPO

On March 26, Versartis (VSAR) completed its initial public offering as it sold 6.9 million shares of its common stock at an offering price of $21 per share. The endocrine-focused biopharmaceutical company raised approximately $132.4 million after deducting discounts to the underwriter along with commissions and estimated expenses related to the offering. The market responded well to the latest biotechnology offering. As of the closing price of $30.05 on March 31, Versartis traded at a 43% premium to its IPO offering price.

Company And Market Overview

Versartis is a developing biopharmaceutical company looking to address the treatment of growth hormone deficiency [GHD]. The company is largely focused on a single product candidate found in VRS-317....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details